Therapy Directory

Capecitabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention. Browse Capecitabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

365

Shown on this page

Local indexed summaries

365

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Capecitabine. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 365 matching trials for Capecitabine.

Indexed local directory records.

Top conditions

Breast Cancer 52 Colorectal Cancer 26 Pancreatic Cancer 24 Gastric Cancer 22 Metastatic Breast Cancer 18 Cancer 12

Top sponsors

National Cancer Institute (NCI) 26 M.D. Anderson Cancer Center 17 Alliance for Clinical Trials in Oncology 13 AstraZeneca 13 Hoffmann-La Roche 13 Merck Sharp & Dohme LLC 13

Top locations

New York, New York 105 Houston, Texas 91 Boston, Massachusetts 82 Los Angeles, California 78 Nashville, Tennessee 70 Chicago, Illinois 65

Indexed official records

Open in full search

Conditions: Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Antiandrogen, SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Rochester, Minnesota • Chapel Hill, North Carolina

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin hydrochloride, Epirubicin hydrochloride, Olaparib, Paclitaxel, Patritumab deruxtecan, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: Gastroesophageal Adenocarcinoma
Interventions: 5-Fluorouracil (5-FU), AZD0901, Capecitabine, FLOT Chemotherapy, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more

Conditions: Breast Neoplasms
Interventions: Capecitabine, Liposomal doxorubicin, Nab-paclitaxel, Paclitaxel, Patritumab deruxtecan, Trastuzumab deruxtecan; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 33
States / cities: Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms, Triple Negative Breast Neoplasms
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Epirubicin, Olaparib, Paclitaxel, Pembrolizumab, Rescue Medication, Sacituzumab tirumotecan; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 51
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Triple-Negative Breast Cancer
Interventions: Capecitabine, Pembrolizumab, Sacituzumab tirumotecan; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 84
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 72 more

Conditions: Breast Neoplasms
Interventions: Capecitabine, Liposomal doxorubicin, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Sacituzumab tirumotecan; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more

Conditions: Advanced Cancer, Esophageal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Carcinoma, Metastatic Cancer, Solid Tumor
Interventions: 5Fluorouracil, Capecitabine, Givastomig, Leucovorin, Nivolumab, Oxaliplatin; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Goodyear, Arizona • Duarte, California • Boston, Massachusetts

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, AZD0901, Capecitabine, FOLFOX, Rilvegostomig, Volrustomig, XELOX; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Baton Rouge, Louisiana • Grand Rapids, Michigan + 5 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Irvine, California • Orange, California • Gainesville, Florida + 14 more

Conditions: Gastric Cancer
Interventions: Capecitabine, Cisplatin, Durvalumab, Fluorouracil (5-FU), Oxaliplatin, Pembrolizumab, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Volrustomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Santa Monica, California • Westwood, Kansas • Baltimore, Maryland + 6 more

Conditions: Clinical Stage: Stage II (T3-4, N-), Rectal Adenocarcinoma, Solid Tumor, Solid Tumor, Adult, Stage III (Any T, N+)
Interventions: Intensity Modulated Radiation Therapy (IMRT), TSR-042 or Dostarlimab, capecitabine or 5-FU; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more

About this Capecitabine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Capecitabine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Capecitabine clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

About this Capecitabine clinical trials directory page